Form 4: LifeMD CFO Marc David Benathen Reports Acquisition of 75,000 Shares of Common Stock

LifeMD's Chief Financial Officer, Marc David Benathen, reports acquiring 75,000 shares of common stock on March 31, 2025.

Summary

• On April 2, 2025, Marc David Benathen, the Chief Financial Officer of LifeMD, Inc., filed a Form 4 with the SEC.
• The report details a transaction on March 31, 2025, where Benathen acquired 75,000 shares of LifeMD common stock.
• The acquisition was a grant of performance stock that vested on March 31, 2025, and the price per share was $0.
• Following this transaction, Benathen directly owns 464,554 shares of LifeMD common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by an executive. While insider buying can be seen as positive, this was a grant of performance stock, so it doesn't necessarily reflect a market purchase.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in beneficial ownership by a key executive.

Stakeholder Impact

• The change in ownership may have a minor impact on shareholders, as it reflects the CFO's increased stake in the company.

Key Dates

Keywords

LifeMD, Benathen, Form 4, SEC, Common Stock, Acquisition, CFO, LFMD, Ownership, Performance Stock